Why Celldex Therapeutics Stock Reversed Course in November
Shares of the struggling small-cap biotech Celldex Therapeutics (NASDAQ: CLDX) finally showed some signs of life in November. Specifically, the biotech's stock rose by a healthy 27.6% last month, according to data from S&P Global Market Intelligence. Even so, the drugmaker's shares are still down by 14.4% year to date.
Celldex's stock got a boost last month from its third-quarter earnings release, where the company announced the initiation of two new clinical trials to assess CDX-3379 in recurrent head and neck squamous cell cancer and CDX-1140 in solid tumors. The company also restated that its lead clinical candidate glembatumumab vedotin -- or glemba for short -- remains on track to produce top-line data for its ongoing mid-stage study in triple negative breast cancer (TNBC) sometime in the second-quarter of 2018.
Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Stock
We see a rather positive sentiment for Celldex Therapeutics with 18 Buy predictions and 1 Sell predictions.
With a target price of 62 € there is potential for a 101.3% increase which would mean more than doubling the current price of 30.8 € for Celldex Therapeutics.
